The epilepsy market is expected to reach USD 1.2 Billion by 2032 at 7.4% CAGR during the forecast period 2023-2032. The increasing rate of epilepsy prevalence in the geriatric community and the rise in accident-induced brain injury cases are major factors driving market growth.
COVID-19 Analysis
The new coronavirus has spread worldwide in a relatively short period and has become a pandemic. Many affected patients have symptoms such as dry cough, tiredness, dyspnea, and fever. However, the infection with Covid-19 disrupts multiple tissues, including the kidney, liver, and nervous system. Common neurological symptoms of Covid-19 infection include delirium, depression, fever, and loss of smell and taste. It can cause stroke and epilepsy in rare cases. This has risen the demand for efficient epilepsy cures and medications. Moreover, the growing R&D investments towards COVID 19 treatments may also contribute towards the epilepsy market growth.
Demand is anticipated to increase due to the increased sensitivity risk associated with epilepsy in the elderly. Demand in the epilepsy market can also be fueled by brain injuries, which can lead to post-traumatic epilepsy (PTE) and post-traumatic seizures (PTS). The incidence of neurological illnesses including meningitis and tumors, as well as the development of experimental medications, and the introduction of new pharmaceuticals in developed nations, all have significant impacts on the global need for epilepsy treatments. The improvement in healthcare costs and the growth in personal disposable income are also contributing factors.
R&D investments in the epilepsy industry are growing as a result of emerging trends including companies focusing on finding novel therapies for refractory epilepsy and doctors wanting greater efficacy drugs. Advances in imaging technologies for early diagnosis and the rising popularity of rational polytherapy are major factors driving the expansion of this market. In addition, the epilepsy industry may benefit from the spread of innovative digital healthcare practices like mHealth and telemedicine.
Through regulatory approval, strategic alliances, and mergers and acquisitions with other epileptic market leaders in their various territories and regions, companies in the epilepsy medicines business strive to strengthen their worldwide reach. Most of the big companies are working to strengthen their product portfolio in order to enhance their market share. It is expected that the introduction of new drugs would contribute to the growth of the anti-epileptic drug industry.
Data from the Phase IIb X-TOLE study suggest that the experimental potassium channel opener XEN1101 by Xenon Pharmaceuticals may safely reduce the burden of seizures in patients with focal epilepsy as of October 2023. Randomized, double-blind, parallel-group, placebo-controlled, and involving 325 patients with focal-onset seizures, the most prevalent type of epileptic seizures, the results were obtained from a mid-stage trial. A dose-dependent reduction in seizure burden was observed with XEN1101 therapy, and at all dosage levels, the efficacy was significantly greater than that of placebo. The incidence of seizures decreased by a median of 52.8% at 25 mg and 46.4% at 20 mg after eight weeks of treatment, relative to baseline.LivaNova, a provider of medical technology, has declared the SenTiva Duo implanted pulse generator, designed for individuals afflicted with drug-resistant epilepsy, to go into production in February 2023. According to a press release, the dual-pin header of the SenTiva Duo is activated in the event of an irregular pulse, potentially preceding seizures. Furthermore, in addition to day-night and scheduled programming, the device records low heart rate and prone position events and provides the same therapeutic benefits as the original single-pin SenTiva.January 2023: For the treatment of epilepsy, Topiramate Extended-Release Capsules from Zydus Lifesciences, manufactured by Zydus Pharmaceuticals (USA) Inc., will become commercially available in the United States. The pharmaceutical behemoth is now authorized to market the medication in USP 25 mg, 50 mg, and 100 mg capsules, as the USFDA has granted prior approval for such sales. For certain types of epilepsy, the extended-release capsule formulation of topiramate may be beneficial as an initial monotherapy measure for patients aged 6 years and older.
Data from the Phase IIb X-TOLE study suggest that the experimental potassium channel opener XEN1101 by Xenon Pharmaceuticals may safely reduce the burden of seizures in patients with focal epilepsy as of October 2023. Randomized, double-blind, parallel-group, placebo-controlled, and involving 325 patients with focal-onset seizures, the most prevalent type of epileptic seizures, the results were obtained from a mid-stage trial. A dose-dependent reduction in seizure burden was observed with XEN1101 therapy, and at all dosage levels, the efficacy was significantly greater than that of placebo. The incidence of seizures decreased by a median of 52.8% at 25 mg and 46.4% at 20 mg after eight weeks of treatment, relative to baseline.
LivaNova, a provider of medical technology, has declared the SenTiva Duo implanted pulse generator, designed for individuals afflicted with drug-resistant epilepsy, to go into production in February 2023. According to a press release, the dual-pin header of the SenTiva Duo is activated in the event of an irregular pulse, potentially preceding seizures. Furthermore, in addition to day-night and scheduled programming, the device records low heart rate and prone position events and provides the same therapeutic benefits as the original single-pin SenTiva.
January 2023: For the treatment of epilepsy, Topiramate Extended-Release Capsules from Zydus Lifesciences, manufactured by Zydus Pharmaceuticals (USA) Inc., will become commercially available in the United States. The pharmaceutical behemoth is now authorized to market the medication in USP 25 mg, 50 mg, and 100 mg capsules, as the USFDA has granted prior approval for such sales. For certain types of epilepsy, the extended-release capsule formulation of topiramate may be beneficial as an initial monotherapy measure for patients aged 6 years and older.
The high sensitivity risk of elderly epilepsy is expected to fuel consumer demand. In addition, brain damage that can cause post-traumatic epilepsy (PTE) and post-traumatic seizures (PTS) can fuel demand in the epilepsy industry. The worldwide demand for epilepsy is also influenced epilepsy market by primary factors such as developing experimental medicines, the arrival of new drugs in developed regions and the prevalence of neurological disorders such as meningitis and tumors. This rise is further fueled by an improvement in healthcare prices and an increase in disposable income.
Growing Adoption Of Advanced Imaging Technology For Early Diagnosis Contributes To Market Growth
Emerging trends such as businesses focused on designing innovative treatments for refractory epilepsy and doctors requiring higher effectiveness medications is increasing the R&D investments towards the epilepsy market. The growing adoption of rational polytherapy and the advanced imaging technology for early diagnosis also contributes to market growth. Moreover, the adoption of advanced digital healthcare models such as mHealth and telemedicine is likely to create growth opportunities for the epilepsy market.
Rise in Medication Costs Likely to Impede Market Growth
On the other hand, the demand expansion is hampered by a time-consuming prescription approval process, and rising medication costs. Moreover, the low awareness about the challenges of epilepsy can also hinder the epilepsy market growth. Infact, consumers are increasingly petitioning gaming companies and social media platforms to include epileptic warnings.
The research report segments the global market for epilepsy by disorder, diagnosis & care and end-use.
By condition, the epilepsy market is bifurcated into epilepsy drug-resistant/intractable epilepsy and others. The drug-resistant epilepsy segment is expected to hit a value of USD 2.93 billion by the end of the forecast period. The advent of rational polytherapy for treating disease with minimal side-effects is expected to produce substantial revenue for the epilepsy market.
By diagnosis and treatment, the epilepsy market for epilepsy is segmented into diagnosis and treatment. The treatment category is expected to drive the epilepsy market at a 7.91 percent CAGR during the projected period due to the availability of inexpensive medications to treat partial epileptic seizures. In addition, the approval of successful drugs by regulatory authorities will promote the development of the segment. On the other hand, the diagnostic segment is expected to mature at 8.76 percent CAGR over the evaluation period. The use of numerous imaging tests and blood tests to diagnose early on the condition is expected to accelerate segment development tenfold.
Based on the end-users, the epilepsy market is segmented into hospitals, clinics, diagnostic centers, ambulatory surgical centers, and others. The hospital segment is touted to dominate the market growth over the review period, followed by the clinics segment. Moreover, hospitals that encourage the procurement of medicine from hospital premises are likely to promote the market.
Regional Analysis
The epilepsy industry in the region is segmented into the Americas, Europe, Asia Pacific (APAC) and the Middle East and Africa (MEA).
North America Dominates the Market with Superior Healthcare Infrastructure
Among them, the Americas accounted for 41 percent of the share in 2017, led by Europe, APAC, and MEA. North America is a leading contributor to the market due to the availability of well-established healthcare facilities, beneficial government policies aimed at strengthening the healthcare sector, and the presence of substantial research and development programs.
Growing R&D Investments Drive the Europe Market
Europe is expected to have a CAGR of 8.31% over the projected period. Increased investment in research and production of successful medications to cure epilepsy coupled with a high prevalence of the disease is expected to fuel regional demand exponentially.
Development of Novel Drugs to Raise APAC Market Scope
The APAC epilepsy market is set to reach a value of USD 2.04 million during the forecast period due to the high occurrence of condition reported in the country. Also, the countries of India, South Korea and China, which are emerging as viable destinations for researching and producing novel products, will stimulate consumer demand over the forecast period.
Companies active in the epilepsy therapeutics industry plan to strengthen their global reach through authorization by government agencies, partnerships, strategic mergers & acquisitions with other epilepsy market leaders in their respective territories and regions around the world. In order to strengthen their position in the global market for epilepsy therapeutics, robust progressive research and development efforts and product pipelines and growing product approvals are crucial strategies followed by these players. To increase their market share, most of the major players are engaged in reinforcing their product portfolio. It is predicted that the launch of new medicines would facilitate the market expansion of anti-epileptic medication.
Key Players
November 2023: Neurelis announces positive results from a Phase 2 clinical trial of its investigational drug, NLS-2, for the treatment of focal-onset seizures in adults with epilepsy. The trial showed that NLS-2 was safe and effective in reducing the frequency of seizures.OVID Therapeutics announces that it has submitted a New Drug Application (NDA) to the FDA for its investigational drug, OV350, for the treatment of Dravet syndrome. OV350 is a small molecule activator of the KCC2 transporter, which is thought to play a role in the development of Dravet syndrome.Marinus Pharmaceuticals announces that it has received FDA breakthrough therapy designation for its investigational drug, ganaxolone, for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD). CDD is a rare genetic disorder that causes severe epilepsy.
October 2023:Eisai announces that it has received FDA approval for its new drug, Fycompa® (perampanel), for the treatment of partial-onset seizures in adults and adolescents with epilepsy. Fycompa® is a non-competitive AMPA receptor antagonist that is thought to work by blocking the excessive release of glutamate, a neurotransmitter that plays a role in the development of seizures.UCB announces that it has received FDA approval for its new drug, Vimpat® (lacosamide), for the treatment of tonic-clonic seizures in adults and adolescents with epilepsy. Vimpat® is a voltage-gated sodium channel blocker that is thought to work by preventing the excessive firing of neurons, which can lead to seizures.
September 2023:The Epilepsy Foundation of America announces that it has launched a new initiative, the Epilepsy Innovation Fund, to support the development of new and innovative treatments for epilepsy. The Epilepsy Innovation Fund will provide funding to early-stage companies developing new epilepsy drugs and devices.The National Institute of Neurological Disorders and Stroke (NINDS) announces that it has awarded a $100 million grant to a consortium of researchers to develop new treatments for epilepsy. The grant will fund research into a variety of new approaches to epilepsy treatment, including gene therapy, stem cell therapy, and brain-computer interfaces.
Report Overview
This report focuses on the growth of the global epilepsy therapeutics market and consists of an extensive executive summary, including a market snapshot that includes details about different segments of the market. It also offers an overview of market competitiveness in terms of geography and market share analysis by leading participants, providing a detailed analysis of the overall competitive situation emerging in the epilepsy therapeutic market. The study also offers knowledge and data analyses of the global market for its commodity, distribution channel, and regional segments.
Epilepsy Drug Resistant/Intractable Epilepsy
Others
Diagnosis
Treatment
Hospitals
Clinics
Ambulatory Surgical Centers
Diagnostic Centers
Others
| Report Attribute/Metric | Details |
| Market Size | USD 1.2 Billion |
| CAGR | 7.4% |
| Base Year | 2021 |
| Forecast Period | 2023-2032 |
| Historical Data | 2020 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Condition, Diagnosis & Treatment and End-use |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | LivaNova PLC (U.K.), GlaxoSmithKline PLC (U.K.), Eisai Co. Ltd. (Japan), Pfizer Inc. (U.S.), Medtronic PLC (Ireland), UCB SA (Belgium), NeuroPace Inc. (U.S.), GW Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Johnson & Johnson Services Inc. (U.S.), Abbott Laboratories (U.S.) |
| Key Market Opportunities | Growing Adoption Of Advanced Imaging Technology For Early Diagnosis |
| Key Market Drivers | Increasing Incidence of PTE to Drive Market Growth |
Frequently Asked Questions (FAQ) :
Epilepsy market is projected to grow at an 7.4% CAGR between 2023-2032.
The Americas is expected to dominate the epilepsy market.
Epilepsy market is predicted to touch USD 1.2 Billion by 2032.
Rising cases of brain injuries and prevalence of epilepsy among the older generation are the key factors driving the epilepsy market.
Hospitals will dominate the epilepsy market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
